The Latest Cardiac and Vascular News
VANCOUVER and MINNEAPOLIS, May 16, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has received written notification from the Nasdaq Stock Market LLC (the “Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under […]
FDA assigns PDUFA action date of October 8, 2022 Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved Ended Q1 with cash, cash equivalents, restricted cash and investments of $65.6 million BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals […]
— Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries — — Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer — — Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data — — Conference […]
Conference call scheduled for 8:30 a.m. ET today MIAMI, May 13, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the first quarter […]
VANCOUVER and MINNEAPOLIS, MN, May 12, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the quarter ended March 31, 2022. Recent Highlights · Achieved Q1 revenue of approximately $611,000, an increase of 35% over the same period in 2021, […]
BUILDING A SOLID BASE OF VAZALORE® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021 GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.66) […]
Company to host conference call today at 4:30 p.m. ET BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) — SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March 31, 2022. “Our successful first quarter has kickstarted another exciting year for SomaLogic as we […]
Company Remains on Track for FDA Submission of Emergency Department (ED) Myocardial Infarction (MI) Software Product in Q2 2022 & Telehealth Solution in Q4 2022 Management to Host Webcast and Conference Call Today At 4:30 p.m. ET SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company […]
REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment of Fred Driscoll as CFO “Our first quarter progress was highlighted by REN-001’s continued advancement towards the clinic and by the […]
Conference call to be held today at 4:30 PM EDT NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. […]
